Seeking Alpha

Alex S. Gabor's  Instablog

Alex S. Gabor
Send Message
Alex S. Gabor is freelance investigative journalist, bank stock analyst, and financial consultant. He does not personally get paid from anyone for anything published here at Seeking Alpha.
My company:
Church of Infinitology
My blog:
You, Me and the SEC
My book:
Confessions of a Sex Crazed Money Man
View Alex S. Gabor's Instablogs on:
  • IBARC Investigates Edison Research Limited

     

     

    The International Bank Activities Reform Commission (IBARC) is investigating whether or not Edison Investment Research was involved in insider trading in various US Based stocks related to HEMP and MJNA.

    EDISON INVESTMENT RESEARCH LIMITED Edison Investment Research Limited (Edison) is a leading international investment research company. Edison and its subsidiaries (Edison Group) have won industry recognition, with awards both in Europe and internationally. The team of 110 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison's research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York, Sydney and Wellington. Edison is authorised and regulated by the United Kingdom's Financial Services Authority (fsa.gov.uk/register/firmBasicDetails.do?...). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. DISCLAIMER Copyright 2013 Edison Investment Research Limited. All rights reserved. This report has been commissioned by GW Pharmaceuticals and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (NYSEARCA:FAA) (as described in sections 5(c)(1)(a), (b) and (c) of the FAA). It is not intended for retail clients. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct an investment business and, accordingly, does not hold any positions in the securities mentioned in this report. However, their respective directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

    http://www.edisoninvestmentresearch.com/researchreports/gwpharma130313update.pdf
     

    Disclosure: I have no positions in any stocks mentioned, but may initiate a short position in OTCPK:GWPRF, GWPH, OTCPK:HEMP, OTCPK:MJNA over the next 72 hours.

    Additional disclosure: IBARC is funded by the Infinite Freedom Foundations in Budapest, Hungary.

    Apr 10 6:05 PM | Link | Comment!
  • MarketWatch Shows NO SEC Filings For Either HEMP Or MJNA-Short Advisory Letter From IBARC

    MarketWatch Shows No SEC Filings for Either HEMP or MJNA, but this is what you get when you try to drill into their site:

    Edited and Refried From MarketWatch:

    HEMP AND MJNA Stock tips are spilling in from everywhere: on CNBC television, at parties, in the gym. Email boxes are full of pitches for can't-miss moneymakers to buy right now. Even your own scouting can turn up stocks that look like solid-gold opportunities.

    Professional investors follow many different methods to hunt down stocks to recommend, from computerized screening programs to gumshoe field work.

    To see how these stock-screening programs work, check out the American Association of Individual Investors Web site. You'll find several dozen examples. See the AAII stock screeners.

    You can find much information about public companies at their own Web sites. Most publicly traded companies maintain an investor section that contains financial data and timely reports about business conditions, such as 10-Ks and 10Qs. The SEC Web site, www.sec.gov., is also a valuable resource.

    With stocks, though, it's often more important to know what to avoid.

    Here are key mistakes to avoid:

    • Overpriced goods: Be cautious about highfalutin stocks. They may be closer to the end of their run than the beginning, no matter how good the company is.

    • Hunches and headlines: Leave impulse buying for the supermarket. Have patience about selling. Time gives individuals a rare edge because longer horizons make losses less likely.

    • Pump-and-dump scams. Internet chat rooms, bulletin boards, unsolicited emails, newsletters -- even radio and TV ads -- can all be sources of stock touting. Don't take the bait.

    HEMP AND MN\JNA are Love-struck stocks. You may love a stock, but it won't love you back. If losses start to mount, you have to know when to break it off and sell. Best defense: Stay disciplined and diversified. Don't invest too much in penny stocks. Day traders and promoters are the only ones who make money in penny stocks and many of those are sheisters.

    HEMP AND MJNA are bandwagons: You'll almost always be too late. Instead buy into companies with a history of superior earnings, barriers to entry in their field and a track record of wise investment.

    "HEMP and MJNA can and should both cease trading before anyone else gets hurt financially", according to sources close to the International Bank Activities Reform Commission which is looking into naked shorting offshore shares of HEMP and MJNA in large quantities via Soros Fund Management in the Cayman Islands.

    Disclosure: I have no positions in any stocks mentioned, but may initiate a short position in OTCPK:HEMP, OTCPK:MJNA over the next 72 hours.

    Additional disclosure: Any short position entertained would be done offshore, not falling under the jurisdiction of the United States SEC. Calling Tracy Tirey and Julie Lutz of the Colorado Office of the United States Securities and Exchange Commission.

    Apr 04 1:46 PM | Link | Comment!
  • What Does This Have To Do With MJNA?
    It is not clear what the intention behind this latest press release is or how it relates to MJNA but Yahoo Finance is carrying the story on links to the Medical Marijuana Industry.

    Advise to Soros Fund Management? Short another billion shares of HEMP.PK and MJNA.pk until both reach .0001 or cease trading orders are put out by SEC.

    KannaLife Sciences, Inc. Signs Research and Development Agreements With Advanced Neural Dynamics and IteraMed in the Discovery of Novel Neuroprotectants

    GlobeNewswirePress Release: KannaLife Sciences, Inc. - 1 hour 47 minutes ago

     

    NEW YORK, April 4, 2013 (GLOBE NEWSWIRE) -- KannaLife Sciences, Inc. ("KannaLife") announces its collaboration with two experienced drug discovery organizations: Advanced Neural Dynamics and IteraMed. KannaLife will fund a new drug discovery project related to a laboratory validated phytochemical. The founding science is based on the licensed technology of Dr. A. J. Hampson at the Laboratory of Cellular and Molecular Regulation within the National Institutes of Mental Health. Dr. Hampson's research has shown that this phytochemical is neuroprotective in cortical neuronal cultures exposed to toxic levels of glutamate or oxidative stress.

    IteraMed and Advanced Neural Dynamics are located at the Pennsylvania Biotechnology Center. The Pennsylvania Biotechnology Center is a 112,000 square-foot biotechnology incubator in Doylestown, PA, houses one of the richest botanical collections in the world and is home to several and approximately thirty life sciences companies and several non-profit organizations. Dean Petkanas, CEO of KannaLife, stated: "This opportunity to begin our research and development program at the Pennsylvania Biotechnology Center, would not be possible without the support and financial backing of our investors, Medical Marijuana, Inc. and CannaVEST. The Pennsylvania Biotechnology Center has a scientifically rich environment in liver, neurological and botanical science, areas vital to KannaLife. Having this shared vision and support from MJNA and CannaVest is crucial to the long range research and development efforts planned between KannaLife, IteraMed and Advanced Neural Dynamics."

    About Advanced Neural Dyanamics ("AND"): AND is a drug discovery company founded in October 2008 by Dr. Douglas Brenneman, an expert in the pharmacology of small molecules and neuropeptides. AND's focuses on developing novel small molecule neuroprotective therapeutics for the treatment of neurological diseases. AND's neuroprotective drug discovery strategy is differentiated by the use of primary neural cultures derived from the central nervous system combined with biochemical, molecular and immunocytochemical methods that measure cellular responses to identify products that will be safer and more effective than currently approved therapies.

    About IteraMed: IteraMed draws on the experience of experienced medicinal and pharmacology scientists with experience in a variety of disease areas including central nervous system disorders (depression, anxiety, neuroprotection), neuropathic pain, cardiovascular disease, oncology, and infection. IteraMed offers "value added" organic synthesis, medicinal chemistry consulting, and internal drug discovery. IteraMed supports a variety of industries including forensics testing laboratories, start-ups, and large pharmaceutical companies. For more information, please visit the company's website at: www.iteramed.com

    About KannaLife:

    KannaLife Sciences, Inc. is a late stage bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. KannaLife Sciences currently holds an exclusive license with National Institutes of Health -- Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent"). For more information, please visit the company's website at:www.kannalife.com

    About Medical Marijuana Inc. (MJNA):

    MJNA's mission is to be the premier cannabis and hemp industry innovator, leveraging its team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. For more information, please visit the company's website at: www.medicalmarijuanainc.com

    About CannaVest (CANV):

    CannaVest is in the business of developing, producing, marketing and selling end consumer products containing the hemp based compounds with a focus on Cannabidiol (NYSE:CBD). CannaVest seeks to take advantage of an emerging worldwide trend to re-energize the production of industrial hemp and to foster its many uses for consumer health and wellness benefits as well as in the pharmaceutical industry.

    Contact:

    Dean Petkanas
    info@kannalife.com
    516-669-3219
    Apr 04 10:53 AM | Link | 2 Comments
Full index of posts »
Latest Followers

StockTalks

  • BRK.A short another million shares.
    May 2, 2013
  • BANR: Keep buying until you see the red in their eyes.
    May 2, 2013
  • C sell short a billion shares from Cayman Islands
    May 2, 2013
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.